1. Home
  2. NTLA vs VTEX Comparison

NTLA vs VTEX Comparison

Compare NTLA & VTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • VTEX
  • Stock Information
  • Founded
  • NTLA 2014
  • VTEX 1999
  • Country
  • NTLA United States
  • VTEX United Kingdom
  • Employees
  • NTLA N/A
  • VTEX N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • VTEX Computer Software: Prepackaged Software
  • Sector
  • NTLA Health Care
  • VTEX Technology
  • Exchange
  • NTLA Nasdaq
  • VTEX Nasdaq
  • Market Cap
  • NTLA 959.4M
  • VTEX 1.2B
  • IPO Year
  • NTLA 2016
  • VTEX 2021
  • Fundamental
  • Price
  • NTLA $9.53
  • VTEX $6.58
  • Analyst Decision
  • NTLA Buy
  • VTEX Buy
  • Analyst Count
  • NTLA 18
  • VTEX 4
  • Target Price
  • NTLA $50.53
  • VTEX $9.75
  • AVG Volume (30 Days)
  • NTLA 3.2M
  • VTEX 648.2K
  • Earning Date
  • NTLA 02-20-2025
  • VTEX 02-25-2025
  • Dividend Yield
  • NTLA N/A
  • VTEX N/A
  • EPS Growth
  • NTLA N/A
  • VTEX N/A
  • EPS
  • NTLA N/A
  • VTEX 0.05
  • Revenue
  • NTLA $43,086,000.00
  • VTEX $225,906,000.00
  • Revenue This Year
  • NTLA $50.68
  • VTEX $17.10
  • Revenue Next Year
  • NTLA N/A
  • VTEX $17.73
  • P/E Ratio
  • NTLA N/A
  • VTEX $138.62
  • Revenue Growth
  • NTLA N/A
  • VTEX 21.27
  • 52 Week Low
  • NTLA $9.25
  • VTEX $5.60
  • 52 Week High
  • NTLA $34.87
  • VTEX $9.59
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 36.07
  • VTEX 59.51
  • Support Level
  • NTLA $9.93
  • VTEX $6.46
  • Resistance Level
  • NTLA $10.73
  • VTEX $6.93
  • Average True Range (ATR)
  • NTLA 0.66
  • VTEX 0.23
  • MACD
  • NTLA 0.08
  • VTEX 0.06
  • Stochastic Oscillator
  • NTLA 13.12
  • VTEX 64.29

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

Share on Social Networks: